Moss 18 December, 2025
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today provided an update on the development of its turbidimetric NT-proBNP assay, which remains the company’s highest-priority pipeline project.
Throughout the fourth quarter of 2025, Gentian made solid progress in advancing the assay toward final product verification. Continued refinement of the calibration approach has led to further improvements in the assay’s analytical performance. To ensure a high-quality and robust product, the company has prioritised additional refinement work ahead of the research-use-only (RUO) introduction, leading to a minor delay compared with earlier expectations. Clinical performance evaluations with external partners are ongoing, and the company expects to provide an update on the RUO product during the first quarter of 2026.
Gentian Diagnostics continues to target the launch of a CE-marked NT-proBNP assay in the fourth quarter of 2026, in line with previous communication.
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)